// App-Quantinova.ai

7042 : Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).

Researchers

Presenter

  • Ghayas C. Issa

Principal Investigators

  • Hagop M. Kantarjian

  • Farhad Ravandi

  • Deborah A. Thomas

  • Maria Khouri

  • Guillermo Garcia-Manero

  • Rebecca S. Garris

  • Jorge E. Cortes

  • Nicholas James Short

  • Koji Sasaki

  • Heather M Schroeder

  • Tapan M. Kadia

  • Srdan Verstovsek

  • Naval Guastad Daver

  • Nitin Jain

  • Marina Konopleva

  • Susan Mary O'Brien

  • Elias Jabbour

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of California, Irvine, Fullerton, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

Drug/Treatment

  • Methotrexate

  • Asparaginase

  • Cytarabine liposomal

  • ofatumumab Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01363128

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved